# US 2021/0275628 A1 · Bacteriocins to improve vaginal colonization of hydrogen peroxide producing lactobacillus for female reproductive health

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275628 A1
- Document ID: US20210275628A1
- Status: Published application
- Kind: A1
- Application number: 17/187,535
- Filed: 2021-02-26
- Published: 2021-09-09
- Earliest claimed: 2018-08-30
- Assignees: Osel, Inc.
- Applicants: Osel, Inc.
- Inventors: Thomas P. Parks; Trine Nilsen
- Web page: https://patentgrep.com/patent/US20210275628A1

## CPC

- A61K 38/164: {from bacteria}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/4164: 1,3-Diazoles
- A61K 31/4168: having a nitrogen attached in position 2, e.g. clonidine
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61P 15/02: for disorders of the vagina
- C07K 14/335: from Lactobacillus (G)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention provides for methods of increasing levels of healthy vaginal bacteria by treating the vaginal mucosa with bacteriocins derived from Lactobacillus paragasseri, Lactobacillus gasseri, and other bacterial strains. The bacteriocins are surprisingly advantageous as being selectively active against Lactobacillus iners but relatively inactive against H2O2-producing Lactobacillus species. Because L. iners is involved in the onset and maintenance of vaginal dysbiosis, selective removal of this bacterium from the vaginal microbiome treats or prevents conditions associated with vaginal dysbiosis, such as bacterial vaginosis and its sequelae.

## Claims

### Claim 1

A bacteriocin composition comprising at least one pharmaceutically acceptable excipient; and at least one isolated peptide, or a combination of isolated peptides, wherein:
i) the at least one isolated peptide, or combination of isolated peptides, has selective bactericidal activity against L. iners;
ii) the at least one isolated peptide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and an isolated peptide having 90% sequence identity to one of SEQ ID NOs:1, 2, 3, or 4; and
iii) the bacteriocin composition is a formulation suitable for intravaginal applications, and wherein the at least one isolated peptide, or combination of isolated peptides, is present in an amount sufficient to exhibit bactericidal properties of the bacteriocin composition.

### Claim 2 (depends on 1)

The bacteriocin composition of claim 1, wherein the isolated peptide is SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 1)

The bacteriocin composition of claim 1, wherein the combination of peptides comprises isolated peptides SEQ ID NO:1 and SEQ ID NO:2; SEQ ID NO:3 and SEQ ID NO:4; or SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4.

### Claim at position 5

7-8. (canceled)

### Claim 9 (depends on 1)

The bacteriocin composition of claim 1, wherein the formulation is a gel, cream, ointment, foam, film, capsule, tablet, powder, pessary, insert, or suppository suitable for topical intravaginal applications.

### Claim 10 (depends on 1)

The bacteriocin composition of claim 1, wherein the amount of peptide, or combination of peptides, is between 0.001% (w/w) and 3% (w/w).

### Claim 11 (depends on 1)

The bacteriocin composition of claim 1, further comprising at least one antibiotic active against BV-associated organisms.

### Claim 12 (depends on 11)

The bacteriocin composition of claim 11, wherein the at least one antibiotic is selected from the group consisting of clindamycin, metronidazole, secnidazole, tinidazole, and astodrimer sodium.

### Claim 13 (depends on 1)

A method of treating a patient having low levels of H2O2-producing vaginal Lactobacillus and a Nugent score of at least 4, the method comprising:
intravaginally administering to the patient the bacteriocin composition of claim 1 an amount sufficient to decrease levels of L. iners and to promote growth of endogenous H2O2-producing vaginal Lactobacillus.

### Claim 14 (depends on 13)

The method of claim 13, further comprising administering to the patient at least one antibiotic active against BV-associated organisms, wherein the antibiotic is administered in an amount sufficient to decrease levels of BV-associated organisms.

### Claim 15 (depends on 13)

The method of claim 13, further comprising administering to the patient a live bacterial composition comprising H2O2-producing vaginal Lactobacillus, wherein the live bacterial composition is administered in an amount sufficient to promote growth of administered H2O2-producing vaginal Lactobacillus.

### Claim 16

(canceled)

### Claim 17 (depends on 13)

The method of claim 13, wherein the isolated peptide is SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4.

### Claim at position 15

18-20. (canceled)

### Claim 21 (depends on 13)

The method of claim 13, wherein the combination of peptides comprises isolated peptides SEQ ID NO:1 and SEQ ID NO:2; SEQ ID NO:3 and SEQ ID NO:4; or SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO: 4.

### Claim at position 17

22-23. (canceled)

### Claim 24 (depends on 13)

The method of claim 13, wherein the amount of the at least one peptide, or combination of isolated peptides, is between 0.001% (w/w) and 3% (w/w).

### Claim 25 (depends on 14)

The method of claim 14, wherein the at least one antibiotic is selected from the group consisting of clindamycin, metronidazole, secnidazole, tinidazole, and astodrimer sodium.

### Claim 26 (depends on 14)

The method of claim 14, wherein the amount of antibiotic is between about 30 mg to about 2000 mg per daily dose.

### Claim 27 (depends on 14)

The method of claim 14, wherein the antibiotic is administered to the patient once daily for up to 7 days.

### Claim 28 (depends on 14)

The method of claim 14, wherein the amount of antibiotic is administered concurrently with the amount of the at least one isolated peptide, or combination of isolated peptides.

### Claim 29 (depends on 15)

The method of claim 15, wherein the H2O2-producing vaginal Lactobacillus is selected from the group consisting of L. crispatus, L. jensenii, L. gasseri, and combinations thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein the H2O2-producing vaginal Lactobacillus is L. crispatus CTV-05.

### Claim 31 (depends on 13)

The method of claim 13, wherein the amount of the at least one isolated peptide, or combination of isolated peptides, is an amount sufficient to prevent or treat BV in the patient, or an amount sufficient to prevent PTB in the patient, or an amount sufficient to prevent IVF failure in the patient.

### Claim at position 26

32-33. (canceled)
